Natera, Inc. and Eledon Pharmaceuticals, Inc. have entered a strategic partnership to use Natera’s Prospera kidney transplant assessment test as the exclusive donor-derived cell-free DNA monitoring assay in Eledon’s planned Phase 3 trial of tegoprubart. The global study is expected to begin in late 2026 and enrol about 600 kidney transplant recipients at more than 100 centres, testing tegoprubart against tacrolimus in a regulatory-stage effort to prevent rejection.
Why combining therapeutic development with molecular graft surveillance changes the Phase 3 evidence strategy
The most important element of the partnership is not simply the selection of a laboratory assay. It is the decision to build serial molecular monitoring into a pivotal therapeutic programme at a scale large enough to examine how graft injury evolves under two different immunosuppressive strategies. Conventional kidney transplant trials rely heavily on biopsy-proven acute rejection, graft loss, death and measures of kidney function. Those outcomes remain essential, but they may identify injury only after the biological process is already established or may fail to explain why kidney function has changed.
Prospera measures donor-derived cell-free DNA released into a recipient’s bloodstream when transplanted tissue is injured. In Eledon’s Phase 3 programme, repeated testing could create a timeline of molecular graft stress before, during and after clinically apparent rejection events. That may help investigators distinguish a stable treatment effect from isolated creatinine fluctuations, identify patterns that precede biopsy findings and examine whether tegoprubart protects the graft in ways that are not immediately visible through routine laboratory monitoring.
However, the diagnostic layer does not reduce the burden on Eledon to deliver a conventionally persuasive Phase 3 result. Donor-derived cell-free DNA is a marker of allograft injury, not a stand-alone explanation of its cause. Elevated levels can prompt further evaluation, but biopsy, clinical assessment, infection testing and other laboratory data remain necessary to determine whether rejection is present and what type of rejection has occurred.
How Prospera could reveal treatment differences that conventional kidney function measures may miss
Tacrolimus is effective at suppressing rejection, but its kidney toxicity can complicate the interpretation of post-transplant renal function. A patient may show declining estimated glomerular filtration rate because of rejection, calcineurin inhibitor toxicity, infection, haemodynamic stress or another form of graft injury. A therapeutic candidate designed to avoid calcineurin inhibition therefore needs more than a higher average kidney function measurement. It needs evidence showing that improved function is not being purchased at the cost of weaker immune control.
Longitudinal donor-derived cell-free DNA monitoring could help address that tension. If tegoprubart-treated recipients maintain stronger kidney function while showing molecular injury patterns comparable with or better than those seen with tacrolimus, the total evidence package would become more credible. If estimated glomerular filtration rate improves but donor-derived cell-free DNA elevations, biopsies or donor-specific immune findings indicate greater underlying injury, the apparent renal benefit would become harder to interpret.
The value will depend on prespecified analyses, sampling consistency and the relationship between Prospera results and clinical events. An extensive dataset can still become exploratory noise when collection schedules vary, thresholds are applied retrospectively or investigators do not clearly define how molecular findings will be integrated with biopsy and endpoint adjudication. The Phase 3 protocol therefore matters as much as the assay itself.
Why the planned non-inferiority design must still prove tegoprubart can match tacrolimus on rejection control
Eledon’s planned primary endpoint is expected to assess whether tegoprubart is non-inferior to tacrolimus at 52 weeks on a composite of biopsy-proven acute rejection, graft loss and death. This is a strategically logical design because tacrolimus remains deeply embedded in kidney transplant immunosuppression and sets a high efficacy benchmark. A new therapy may not need to show superior rejection prevention if it can preserve comparable graft protection while reducing kidney, metabolic, neurological or cardiovascular toxicity.
Non-inferiority trials are also demanding. The selected margin must be clinically acceptable, treatment adherence must remain strong and missing data must be managed conservatively. Variability in biopsy practices across more than 100 transplant centres could complicate interpretation, particularly if local thresholds for performing biopsies differ. Central pathology review, consistent rejection definitions and disciplined follow-up will be crucial to prevent operational variation from obscuring a true treatment difference.
Prospera may support this design by providing a standardised molecular signal across participating centres, but it cannot compensate for weak endpoint execution. Regulators will still focus on the clinical composite, safety profile and durability of graft function. Molecular monitoring will be most persuasive when it explains and reinforces those results rather than competing with them.
What the Phase 2 BESTOW results support and why they remain insufficient for regulatory confidence
The Phase 2 BESTOW programme gives Eledon a credible reason to advance tegoprubart. The randomised, open-label study enrolled 127 kidney transplant recipients, and extension data have shown sustained separation in estimated glomerular filtration rate between tegoprubart and tacrolimus. At 18 months, the reported mean difference was about 12 millilitres per minute per 1.73 square metres, with no biopsy-proven acute rejection events observed in the tegoprubart group after the first six months of treatment.
Those findings support the hypothesis that blocking CD40 ligand may preserve kidney function without sacrificing longer-term rejection control. Reported differences in several adverse events and patient-reported symptom measures also strengthen the argument that a calcineurin inhibitor-free regimen could reduce some of the treatment burden associated with tacrolimus.
The limitations are equally important. BESTOW was open label, the sample was modest and extension analyses include patients who completed the initial study and chose to continue. That creates the possibility of selection effects and limits certainty about uncommon safety events. The kidney function difference is encouraging, but a larger controlled trial is needed to determine whether it persists across broader recipient populations, donor types, immunological risk groups and transplant-centre practices.
How tegoprubart differs from tacrolimus and belatacept without eliminating immunosuppression risk
Tegoprubart is a humanised monoclonal antibody targeting CD40 ligand, a costimulatory pathway involved in T-cell and B-cell activation. The mechanism is intended to provide more selective immune modulation than calcineurin inhibition and to avoid direct calcineurin inhibitor nephrotoxicity. The antibody was also engineered to reduce Fc receptor interactions associated with platelet activation, an important design consideration because earlier anti-CD40 ligand programmes were affected by thromboembolic risk.
The relevant commercial and clinical comparison extends beyond tacrolimus. Belatacept already offers an approved costimulation-blocking approach for certain adult kidney transplant recipients and has demonstrated that a biologic-based, calcineurin inhibitor-free strategy can preserve renal function. Its use is constrained by eligibility, administration requirements, rejection considerations and risks including post-transplant lymphoproliferative disorder, particularly in recipients without prior Epstein-Barr virus exposure.
Tegoprubart will therefore need to demonstrate differentiation rather than merely novelty. Clinicians will examine the timing and severity of rejection, infection rates, malignancy signals, donor-specific antibody development, administration burden and the feasibility of combining the drug with other components of the immunosuppressive regimen. A more targeted mechanism does not make immune suppression risk-free, and Phase 3 must be large and long enough to identify clinically meaningful trade-offs.
What Natera gains from embedding Prospera in a large global therapeutic development programme
For Natera, the partnership creates a route to generate a large prospective dataset linking serial Prospera measurements with treatment assignment, biopsy outcomes, kidney function and major clinical events. This is different from routine commercial testing because the assay will be used within a structured, multicentre drug trial with defined follow-up and an active comparator.
The resulting evidence could strengthen the case for donor-derived cell-free DNA as a standard component of therapeutic trials and post-transplant surveillance. It may also help Natera demonstrate how its two-threshold approach, which evaluates both the fraction and calculated quantity of donor-derived cell-free DNA, performs across different immunosuppressive mechanisms and stages of graft recovery.
Commercial expansion is not automatic. A useful trial biomarker does not necessarily become a reimbursed routine test in every market, and transplant centres differ in surveillance practices, biopsy thresholds and budget constraints. Natera will need the study to show that repeated testing changes clinical interpretation or decision-making, not only that the assay produces additional measurements.
Which operational and biological limitations could weaken the value of longitudinal dd-cfDNA monitoring
The Phase 3 trial will require consistent blood collection, sample handling, shipping and reporting across more than 100 centres. Delays or missing samples could reduce the completeness of longitudinal profiles, while differences in the timing of testing after surgery, infection or biopsy may introduce variability. Global participation adds further complexity because laboratory logistics, clinical workflows and local standards are not uniform.
Biological interpretation is another limitation. Donor-derived cell-free DNA can rise with graft injury that is unrelated to rejection, including infection and other tissue stress. Relative percentages can also be influenced by changes in the recipient’s total cell-free DNA. Prospera’s use of both fraction and quantity is intended to improve interpretation, but no threshold eliminates the need for clinical context.
There is also a risk that intensive monitoring increases follow-up procedures without improving outcomes. More molecular alerts could lead to additional biopsies, treatment changes or anxiety if the positive predictive value is insufficient in lower-risk recipients. The strongest Phase 3 evidence would therefore connect Prospera trajectories with adjudicated rejection, kidney function and treatment decisions while showing that the information is clinically actionable.
What clinicians, regulators and transplant centres are likely to watch as Phase 3 begins
The first question will be whether Eledon starts the study on schedule in late 2026 and enrols a sufficiently representative population. The second will be whether tegoprubart matches tacrolimus on the primary clinical composite while sustaining the kidney function advantage suggested in Phase 2. Safety surveillance will need particular attention because uncommon infections, malignancies, thromboembolic events and immune complications may emerge only with broader exposure.
Observers will also examine whether Prospera identifies meaningful differences before conventional measures change and whether those signals correlate with central biopsy findings. A consistent relationship would support the assay as a development tool and could improve understanding of how next-generation immunosuppression affects graft biology. An inconsistent relationship would limit the partnership’s significance even if the drug trial itself succeeds.
The strategic opportunity is substantial because kidney transplantation has seen limited therapeutic change despite persistent concerns about the long-term consequences of calcineurin inhibitors. Yet the programme still faces two separate proof requirements. Eledon must show that tegoprubart can protect transplanted kidneys with an acceptable safety profile, while Natera must show that serial molecular surveillance adds interpretable and actionable evidence. Phase 3 will determine whether combining those ambitions produces a stronger standard of evidence or simply a more complex trial.
Why Natera’s Prospera could reshape how Eledon measures kidney transplant injury in Phase 3 added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →